Beruflich Dokumente
Kultur Dokumente
Any attempt to share your access to our website or forwarding your copy to a
non-subscriber will disqualify your membership and we will be compelled to stop your supply and forfeit your subscription thereafter without any refund to you.
T I M E S
A TIME COMMUNICATIONS PUBLICATION
VOL XXVI No.14 Monday, 6 12 February 2017 Pgs.20 Rs.18
BAZAR.COM
Remonetising Bharat
Finance Minister Arun Jaitley has begun remonetizing India and the Union Budget 2017-18 was an indication of this.
Sandwiched between the demonetisation announced on 8 November 2016 and State Polls of mid-February and March
2017, it was a tight rope walk for the FM. After the demonetisation pain, it was time for the aam aadmi to gain and that
is what came in small and medium doses. FM stuck to the simple principle of creating gains and presented the most
decisive budget of the NaMo government.
The simple formula of GDP = C (consumer spending) + I (investments and capital formulation) + G (government
spending) + E (exports and imports) was applied. He knew well that the pain that of the currency swap will not be
healed till the economy takes off and the kick start will be though government spending. In the formula, G thus became
the centrifugal force, which the FM chose to leverage tax buoyancy and the Income Declaration Scheme (IDS) revenues
to pump this prime spending.
Rural Bharat and agriculture remain the key focus areas. The budget proposed various initiatives that promise to
improve farmers income and productivity like higher investment in irrigation, higher coverage under crop insurance, a
fund to develop dairies, wider access to credit and expansion of agri-markets by de-notifying fruits and vegetables.
Agri: Agri boost initiatives include:
Agri credit raised to Rs.10 lakh crore
Incentives offered to entrepreneurs setting up mini labs for soil testing
Coverage under Fasal Bima Yojana raised to 40% in 2017-18 and to 50% in 2018-19
60 days interest waiver on loans to farmers
Bring farmers closer to agro-processing units for better LIVE MARKET DAILY
pricing realisation (Nifty, Bank Nifty & Live Market Calls)
Model law on contract-farming is underway
Identifies intra-day Trading Opportunities and also
Corpus of long-term irrigation fund raised to Rs.40000 provides positional calls for a day or two depending
crore
on the range of the target.
Expansion of national agriculture market (e-NAM) to
585 APMCs.
Available daily by SMS or on Live Chat
Last but not the least, the government continues to Subscription Rate: Rs.4000 per month & Rs.36000 p.a.
pursue doubling of farmers income in 5 years as Contact us on 022-22616970 for a FREE 2-Day Trial.
announced in last years budget.
Rural: Rural thrust comes with allocation of Rs.48000 crore to MNREG (Mahatma Gandhi National Rural Employment
Guarantee Scheme) for 2017-18. MNREGA should create productive assets to improve farm productivity and incomes.
This single measure will contribute greatly to drought-proofing of gram panchayats, said Jaitley.
TRADING ON TECHNICALS
Supply Zone for profit booking
By Hitendra Vasudeo
Sensex Daily Trend DRV Weekly Trend WRV Monthly Trend MRV Last week, the
Last Close 28240 Up 27479 Up 27155 Up 26411 Sensex opened
at 27866.80,
attained a low at 27590.10 and moved to a high of 28299.92 before it finally closed the week at 28240.52 and thereby
showed a net rise of 358 points on a week-to-week basis.
Daily
The 61.8% retracement has been crossed. The next retracement levels of the fall from 29077 to 25717 are placed at
28356 and 28698 respectively.
RSI is in the overbought zone and exhaustion on the daily chart could happen at the current level or at the higher
retracement level of 28356 or at 28698.
Weekly
Expect the Sensex to move towards the 78.6% retracement of the fall from 29077 to 25717. The 78.6% and 88.6%
retracements are placed at 28356 and 28698.
Wave (d) could be in place and retrace to 78.6% or to 88.6%. The supply zone is 29162-30024, which is the peak zone
on the weekly historical chart. The peak was at 30024 and in the same week the low was 29162. Therefore, the supply
zone is 29162-30024.
Weekly support is at 28043-27787-27500.
Yearly Levels for 2017
Last Close Level 1 Level 2 Center Point Level 3 Level 4 The yearly open-close logic is as follows: If the
27238 16472 23054 26066 29637 36220 Sensex is above the open (26711) and also above
Weekly Up
Scrip Last Level Level Center Level Level Relative
Reversal Trend
Close 1 2 Point 3 4 Strength
Value Date
Weak Demand Demand Supply Supply
below point point point point
NMDC 148.30 143.0 144.2 147.1 151.2 158.2 72.5 145.0 06-01-17
INDRAPRASTHA GAS 967.45 933.1 940.1 960.4 987.7 1035.2 70.2 944.8 09-12-16
SAIL (STEEL AUTHORIT 65.55 62.8 63.2 65.2 67.6 72.0 69.2 61.2 06-01-17
VAKRANGEE LIMITED 309.60 303.1 303.8 308.9 314.7 325.6 68.4 302.4 13-01-17
VESUVIUS INDIA 1240.00 1190.0 1206.7 1223.3 1256.7 1306.7 67.9 1196.3 30-12-16
Weekly Down
Scrip Last Level Level Center Level Level Relative
Reversal Trend
Close 1 2 Point 3 4 Strength
Value Date
Demand Demand Supply Supply Strong
point point point point above
BHARTI INFRATEL 299.75 197.6 270.1 312.8 342.5 355.6 29.43 340.16 27-01-17
BLUE DART EXPRESS 4320.00 4041.7 4248.7 4384.3 4455.7 4520.0 32.48 4438.00 03-02-17
ALEMBIC PHARMA 557.30 513.9 543.5 559.2 573.1 575.0 35.06 581.81 16-12-16
EXIT LIST
Note: SA-Strong Above, DP-Demand Point, SP- Supply Point, SA- Strong Above
BUY LIST
Note: SA-Strong Above, DP-Demand Point, SP- Supply Point, SA- Strong Above
Scrip Last Close Demand point Demand point Demand Point Weak below Supply Point Monthly RS
VIJAYA BANK 66.65 63.32 61.17 59.03 52.10 99.6 78.79
SUN TV NETWORK 683.85 632.91 612.50 592.09 526.00 978.9 64.53
ZEE LEARN 48.45 48.29 47.82 47.36 45.85 56.2 63.83
INDIAN BANK 289.10 283.60 281.00 278.40 270.00 327.6 63.81
STERLITE TECHNOLOGIE 131.40 128.72 127.53 126.33 122.45 149.0 59.46
TRENT 250.75 248.61 245.40 242.19 231.80 303.0 57.94
GRUH FINANCE 355.10 351.59 349.05 346.51 338.30 394.6 54.58
NATCO PHARMA 722.00 709.41 701.50 693.59 668.00 843.4 50.65
PUNTER PICKS
Note: Positional trade and exit at stop loss or target whichever is earlier. Not an intra-day trade. A delivery based trade for a
possible time frame of 1-7 trading days. Exit at first target or above.
Note: SA-Strong Above, DP-Demand Point, SP- Supply Point, SA- Strong Above, RS- Strength
*Note: Up and Down Trend are based of set of moving averages as reference point to define a trend.
Close below averages is defined as down trend. Close above averages is defined as up trend. Volatility
(Up/Down) within Down Trend can happen/ Volatility (Up/Down) within Up Trend can happen.
! Note: Momentum breakout trend of stocks value(volume*close) between 10-80 lakhs.
TOWER TALK
The share of Sintex Industries may rise substantially on account of wealth creation due to the impending demerger
of the Companys business coupled with softening of interest rates and higher allocation for Swachh Bharat Abhiyan.
VST Tillers Tractors and Shakti Pumps stand to benefit from the populist budget which projects to double
farmers' income by 2022.
BEST BET
Sanofi India Ltd
(BSE Code: 500674) (CMP: Rs.4079.90) (FV: Rs.10)
By Bikshapathi Thota
Sanofi India Ltd (SIL) was incorporated in May 1956 as Hoechst Fedco Pharma Pvt Ltd. Over the years, its name was
changed to Hoechst Pharmaceuticals Pvt Ltd, Hoechst India Ltd, Hoechst Marion Roussel Ltd and Aventis Pharma Ltd.
Sanofi, a leading pharmaceutical company, along with its 100% subsidiary - Hoechst GmbH, are the major shareholders
of SIL which together hold 60.4% of its paid-up share capital.
SILs portfolio includes pharmaceuticals and consumer healthcare products. Within pharmaceuticals, the Company has a
strong presence in diabetes and has built a strong and balanced portfolio with oral and insulin products. It has state-of-
the-art manufacturing facilities at Ankleshwar in Gujarat (chemistry and pharmaceuticals) and Verna Industrial Park in
Goa (pharmaceuticals). Its facility at Medchal in Hyderabad (insulin) is operated by its 100% subsidiary, Shanta Biotech,
and production is likely to start in H2CY17.
Sanofi is a global health care leader that develops and distributes therapeutic solutions worldwide. It offers a wide
variety of therapeutic solutions across Diabetes, Cardiovascular diseases, Anti-Infectives, Central Nervous System,
Consumer healthcare, Nutraceuticals, Anti-histamines, etc. Its four products viz. Lantus, Combiflam, Clexane and
Allegra feature in the list of top 100 pharmaceutical brands.
In the hospital space, SIL supports the IHOP (In Hospitals Protocols) initiative, which aims at developing a common
treatment protocol for diabetes management within hospitals. In the Oral portfolio space, it supported the South Asian
Federation of Endocrine Societies (SAFES) in developing a South Asian consensus on safe and smart use of
sulphonylureas, which was published in the Indian Journal of Endocrinology and Metabolism.
SIL has a diversified portfolio in Cardio-metabolism, Central Nervous System, Intensive Care, Consumer Healthcare,
Gastrointestinal Disorders, Anti-Infectives, Bone & Joint, Respiratory, etc. Having gained the trust and confidence of
physicians and patients, many of its brands are leaders in their respective categories.
SIL manufactures ~90% of its medicines marketed in India indigenously in line with the governments 'Make in India
initiative. Its products are least affected by USFDA issues. The Company has developed an affordable, high quality,
indigenous reusable insulin injection pen - AllStar, which received worldwide recognition for innovation and cost
effectiveness.
Opportunities and Threats: The industry will continue to grow
Financial Performance: (Rs. in crore)
given the rising affordability among the fast growing middle-class
group coupled with improving medical infrastructure and rising Particulars CY14 CY15 CY16E CY17P
insurance penetration. The hospital segment, in particular, is Sales 2042 2245 2510 2768
expected to grow significantly with the continuing expansion of Expenditure 1639 1734 1952 2095
corporate hospitals groups especially in the metros. PBDT 403 510 558 673
The Ministry of Health and Family Welfare has released a list of Net Profit 264 322 354 414
National List of Essential Medicines (NLEM) whose prices are EPS (in Rs.) 115 140 154 180
regulated by the government. During FY16, 106 new molecules
were added and 70 molecules were deleted from the earlier list announced in 2011, because of which the pricing
pressures shall continue.
The industry has to mandatorily follow the Unified Code of Pharmaceutical Medical Practices (UCPMP), a voluntary code
promulgated by the Department of Pharmaceuticals in 2015 to implement ethical marketing practices. SIL already
follows strict guidelines with regard to ethical dealings with Healthcare professionals in the overall interest of the
industry and for the benefit of its patients.
GURU SPEAK
Markets to remain bullish
Interest rate cut is a must
Amid all the speculation and commotion about the Union Budget likely to be populist on account of the elections in five
states in February and March 2017, the Guru Speak column once again came out with its bold and strong conviction
that the forthcoming budget will prove to be A path-breaking budget in the last issue released
in Mumbai on Saturday, 28 January 2017. Speculation was rife about individual tax limit
exemption to increase by at least Rs.50000 from Rs.2.50 lakh to Rs.3 lakh, reduction in
corporate tax, tweaking Long-Term Capital Gains and several goodies here and there to please
the voter classes but nothing of this sort happened.
Believe it or not, the market was quite tense right from 11 am when FM Arun Jaitley started
reading the budget proposal in the Lok Sabha on Wednesday, 1 February 2107. There was
By G. S. Roongta practically no fluctuation in stock prices during his two and a half hour speech. Perhaps for the
first time, the market did not witness any wide fluctuation beyond 25 to 50 Sensex points
throughout the budget speech. But no sooner the budget speech ended, several analysts rushed to enquire if there was
any change capital gains on long-term investment and after realizing that there was no change, the market started rising
without looking back. This clearly means that speculators had short positions on fears of long-term capital gains tax
being either abolished or enhanced to two or three years holding period to qualify for exemption.
The market witnessed a smart rally on Wednesday, 1 February 2017, after several years rising steeply by over 500
points in an intra-day rally as against a fall of 200 points last year on the budget day. The Sensex, however, ended with a
clear sweep of 485.68 points at 28141.64 while the CNX Nifty rose 155 points at 8716.40 thus surpassing several Nifty
resistance levels between 8400 and 8680 or Sensex at 28K at last.
The BSE Sensex, which gained 847 points week
before last ending Friday, 27 January 2017, to Mid-caps or Mad-caps?
close at 27882.46 followed by the Niftys rise by 2017 will be watershed year in the history of stock
292 points at 8642, dismissed all fears of market as it takes off from a weak closure of 2016.
demonetisation and the propaganda and
Leading the charge will be the Mid-caps that are
processions carried out by opposition parties led
by Congress and Mamata Banerji. Narendra Modi likely to outperform the large-caps or index stocks.
has once again proved his strength, Another forecast made by Mr. G.S. Roongta.
foresightedness and strong conviction in his fight
against black money v/s growth.
To encash this opportunity, Money Times will launch
Roongtas Mid-cap Twins comprising two mid-cap
Going back to the history of union budgets
presented by several finance ministers right recommendation every month beginning with 1st
from 1950 till 2017, there are hardly 3 or 4 August 2016.
budgets which proved to be a Dream Budgets, Attractively priced at Rs.2000 per month, Rs.11000
path-breaking or revolutionary (i) Led by Mr. half yearly and Rs.20,000 annually, Roongtas Mid-
Manmohan Singh in 1992; (ii) Mr. P. cap Twins will be available both as print edition or
Chidambaram on 22 July 1996; and now by (iii) online delivery.
Mr. Arun Jaitley on 1 February 2017. Rest of the
Latest edition of Mid-Cap Twins was released on
budgets were just considered as routine
twinkling the tax rates and duties here and there. 1st February 2017
In India, the budget is considered to be most Please book your subscription
important event that decides economic
yardsticks for the year unlike other countries where it is considered as routine just like how a Board of Directors adopt
the Annual Report. This is why the Indian stock markets give so much importance to the budget, which decides the
future course of economy whether it is headed north or south.
STOCK WATCH
By Amit Kumar Gupta
STOCK BUZZ
By Subramanian Mahadevan
SMART PICKS
Budget sets bullish trend for 2017
By Rohan Nalawade
In our previous article headlined Bulls in full control we had rightly advised to buy on dips strategy till 8740, which
was almost achieved last week and our stock recommendations like State Bank of India, ICICI Bank and Reliance
Industries performed well.
As per WD Gann price cycle theory, 6 February 2017 since 5 February is a Sunday, is an important Gann date. The
market is now set for a new high in 2017 and the Nifty may achieve 9300-9600 levels. With 8625 as a major support
level, Nifty may rise to 8800-8920 levels shortly. Bank Nifty is seen supporting the market for new highs and the mid-
caps, too, are warming up.
As far as the budget is concerned, we were positive on sectors like infrastructure, roads, railways, construction,
agriculture, banks, etc and were proven right as the budget presented on 1 February 2017, had various benefits for these
sectors. Further, tax benefits were announced for start-ups and individual tax rate was also reduced from 10% to 5% for
income between Rs.2.5-5 lakh. Overall, the budget was good and productive. Stocks related to banks, mines,
infrastructure and agro products will rise this year.
Among stocks,
Buy BSE Ltd, which got listed with good volumes at Rs.1089 last week, for good returns in the long-term.
Buy Mahindra Finance above Rs.290 for a price target of Rs.320.
Buy IFCI above Rs.30 for a price target of Rs.36-40.
Buy L&T Finance at Rs.101 for a price target of Rs.119-135.
Buy Ashok Leyland above Rs.92 for a price target of Rs.110.
Hold State Bank of India recommended earlier at Rs.250 for a price target of Rs.288.
Hold ICICI Bank recommended earlier at Rs.257 for a price target of Rs.310.
Hold Ambuja Cement recommended earlier at Rs.230 for a price target of Rs.250-265.
MARKET REVIEW
Sensex crosses 28K psychological mark
By Devendra A Singh
The BSE Sensex advanced 358.06 points to close at 28,240.52 and the NSE Nifty closed at 8,740.95 gaining 99.70 points
for the week ending Friday, 3 February 2017.
On the macro economic front, Indias Manufacturing Purchasing Managers Index (PMI) surged to 50.4 in January 2017
from 49.6 in December 2016.
In Budget 2017-18, on Wednesday, 1 February 2017, FM Arun Jaitley proposed to phase out the Foreign Investment
Promotion Board (FIPB). Indias FDI policy is also likely to see further easing in FY18. A total liberalisation of the FDI
policy is on the anvil and the announcement will come in due course of time. The FM also unveiled a string of measures
for Ease of Doing Business and announced an allocation of Rs.396,135 crore for the infrastructure sector.
EXPERT EYE
By Vihari
TECHNO FUNDA
By Nayan Patel
REVIEW
Acknit Industries Ltd Nahar Poly Films recommended on 26-12-16
(BSE Code: 530043) (CMP: Rs.120.80) (FV: Rs.10) at Rs.59 shot up to Rs.66.40 and in same
Incorporated in 1990, Acknit Industries Ltd (Acknit) (formerly Known as issue Aro Granite Industries recommended at
Acknit Knitting Ltd) is one of the largest manufacturers and exporters of Rs.68 shot up to Rs.78.70 during the week.
Disclaimer: Investment recommendations made in Money Times are for information purposes only and derived from sources that are deemed to
be reliable but their accuracy and completeness are not guaranteed. Money Times or the analyst/writer does not accept any liability for the use of
this column for the buying or selling of securities. Readers of this column who buy or sell securities based on the information in this column are
solely responsible for their actions. The author, his company or his acquaintances may/may not have positions in the above mentioned scrip.
City: Pin:
Tel No Mob
Email:
Are you a Investor, Trader, Broker/Sub-Broker, Investment Advisor, Banker